Lyndra, Inc. said today that it closed a $23m Series A round, led by Polaris Partners, to fund the development of its long-acting therapeutic oral delivery platform. Quark Venture, GF Securities, Yonghua Capital, Healthlink Capital, Partners Healthcare, Suffolk Equity and others invested in the round.
The Watertown, Mass.-based company touts its tech as the 1st ultra-long acting, sustained release oral dosage form. Its system enables linear drug release of peptides and small molecules for 7 days or longer from each capsule, the company said.
Get the full story at our sister site, Drug Delivery Business News.
The post Lyndra raises $23m for long-acting drug delivery tech appeared first on MassDevice.
from MassDevice http://ift.tt/2o9Y1Kq
Cap comentari:
Publica un comentari a l'entrada